Skip to main content

Table 1 Patient characteristics (N = 1,218)

From: Antihypertensive drug class and impaired fasting glucose: a risk association study among Chinese patients with uncomplicated hypertension

 

β-blockers

(n = 307)

Thiazide

(n = 196)

CCBs

(n = 322)

RAS

(n = 55)

Others*

(n = 338)

p value

Age (years)

      

<50

85 (27.7)

38 (19.4)

74 (23.0)

9 (16.4)

58 (17.2)

<0.001

50–59

113 (36.8)

62 (31.6)

87 (27.0)

22 (40.0)

84 (24.9)

 

60–69

59 (19.2)

51 (26.0)

70 (21.7)

11 (20.0)

77 (22.8)

 

≥ 70

50 (16.3)

45 (23.0)

91 (28.3)

13 (23.6)

119 (35.2)

 

Mean Age

56.96

60.14

60.80

60.02

63.30

<0.001

(SD)

(11.67)

(11.37)

(13.21)

(12.83)

(13.42)

 

(95% CI)

(55.651,58.27)

(58.54, 61.74)

(59.36, 62.25)

(56.55, 63.49)

(61.87, 64.74)

 

Gender (no./%)

      

Female

200 (65.1)

124 (63.3)

168 (52.2)

33 (60.0)

189 (55.9)

0.008

Male

107 (34.9)

72 (36.7)

154 (47.8)

22 (40.0)

149 (44.1)

 

Payment

      

Fee-waivers

107 (34.9)

68 (34.7)

107 (33.2)

17 (30.9)

96 (28.4)

0.415

Payers

200 (65.1)

128 (65.3)

215 (66.8)

38 (69.1)

242 (71.6)

 

District of residence

      

Shatin

85 (27.7)

44 (22.4)

84 (26.1)

12 (21.8)

135 (39.9)

<0.001

Taipo

31 (10.1)

13 (6.6)

52 (16.1)

5 (9.1)

37 (10.9)

 

Northern

161 (52.8)

127 (64.8)

169 (52.5)

34 (61.8)

134 (39.6)

 

Others

30 (9.4)

12 (6.1)

17 (5.3)

4 (7.3)

32 (9.5)

 

Service type

      

General

264 (86.0)

179 (91.3)

288 (89.4)

48 (87.3)

275 (81.4)

<0.001

FMSC

29 (9.4)

7 (3.6)

27 (8.4)

4 (7.3)

56 (16.6)

 

Staff clinic

14 (4.6)

10 (5.1)

7 (2.2)

3 (5.5)

7 (2.1)

 

Glucose Profile

5.42

5.48

5.46

5.41

5.60

0.786

(mean ± 95% CI)

(5.34, 5.51)

(5.38, 5.59)

(5.37, 5.54)

(5.20, 5.61)

(5.52, 5.68)

 

Period from drug prescription to blood taking (weeks)

7.43

7.00

7.79

6.71

8.00

0.054**

Median (IQR)

(5.86, 10.00)

(5.18, 8.96)

(5.57, 10.32)

(5.00, 10.00)

(6.00, 12.00)

 
  1. (CCB: Calcium channel blockers; RAS: drugs acting on the rennin angiotensin system, IQR: Inter-quartile Ranges)
  2. *Others refer to drug classes including α-blockers, polytherapy, combination therapy, and Misc classes
  3. **Refers to comparison among four drug groups: β-blockers, thiazide diuretics, CCB, RAS)